PhD, 2012, Massachusetts Institute of Technology
BA, 2004, University of California, Berkeley
Mycobacterium tuberculosis (Mtb) is one of the leading causes of death due to infectious disease and infects one-quarter of the world’s population. New drugs, drug regimens, and innovative approaches to limit drug resistance are desperately needed. To facilitate their development, the Rock Lab seeks to provide a more complete understanding of the interaction between Mtb, the host, and antibiotics. The lab is taking a functional and chemical genomic approach to, among other things, identify and characterize high-value, druggable Mtb targets, characterize small molecule inhibitors with novel mechanisms of action, and define the design rules for synergistic antibiotic regimens capable of shortening the course of treatment and reversing drug resistance.